There is strong evidence that psilocybin could play a very important role in a new generation of treatments for those with a variety of mental and physical health conditions. Research into this incredibly promising area is held back by psilocybin's classification as a 'schedule 1' drug. Schedule 1 is for drugs deemed to have 'no medical value'. Psilocybin does not belong there.
PAR.global campaigns for the rescheduling of psilocybin as part of our belief in evidence-based drugs policy. Unjustified barriers to research on this chemical should be safely removed.
Go to our website https://www.par.global/ to sign the gov.uk petition and follow the campaign.
PAR.global is a UK non-profit working as part of the global campaign to reschedule psilocybin.
Company Details
- Employees
- 5
- Founded
- 2022
- Address
- Mental Health Challenges Like Ptsd And Depression In Veteran Populations
- Industry
- Civic And Social Organizations
- NAICS
-
Civic and Social Organizations
- Website
- https://www.par.global/
Par.global Questions
Par.Global's website is https://www.par.global/
Par.Global's LinkedIn profile is https://www.linkedin.com/company/psilocybin-access-rights-global
Par.Global has
5 employees.
View email and phone details for 5
employees at Par.Global.
Par.Global's industry is
Civic and Social Organizations
Par.Global's top competitors are
All Sport Insurance Services Limited,
Women Are The Medicine,
Clerkenwell Health,
Artolution,
Imaginatrix,
Cyber Rabbit,
Ossmo,
Par Global,
Caaveri Enterprises,
Matter Therapies.
Par.Global's categories are Civic and Social Organizations
Par.Global's founding year is 2022
